About HBM HOLDINGS-B Company

We are a clinical-stage biopharmaceutical company incorporated in July 2016 to research and develop differentiated antibody therapies in the fields of tumor immunity and autoimmune diseases. We are committed to the discovery, development, and commercialization of innovative antibody therapies to meet unmet patient needs. Since 2022, we have established two sub-brands, Harbour Therapeutics, which focuses on pipeline development, product cooperation and commercialization, and Nona Biotech, a biotechnology company that provides overall solutions to global partners. In 2023, Harbour Therapeutics and Nona Biotech became the two pillars driving the company's business growth. Rich product portfolio and differentiated pipeline Under HarbourTherapeutics, we have a rich and diverse product pipeline with more than ten potential drug candidates, four of which are in clinical development. HBM9161, HBM4003, HBM7008 and HBM1020 are our main products. bartolizumab (HBM9161) Bartolizumab is an all-human monoclonal antibody that selectively binds to and inhibits neonatal crystal fragment receptors (“FcRn”). FcRn plays a key role in preventing IgG antibody degradation. High levels of pathogenic IgG antibodies induce a variety of autoimmune diseases. As the most advanced clinically advanced FcRN inhibitor developed in Greater China, bartolizumab has the potential to become a breakthrough treatment for many types of autoimmune diseases in Greater China. On October 10, 2022, we reached a licensing agreement with Shiyao Group Enbipu Pharmaceutical Co., Ltd. (“Enbipu Pharmaceutical”, a wholly-owned subsidiary of Shiyao Holding Group Co., Ltd.). According to the agreement, we will grant EnbiPu Pharmaceuticals an exclusive, transferable technical license to develop, produce and commercialize the authorized product bartolizumab (referring to any drug or biological product containing bartolizumab) in the Greater China region (including Hong Kong, Macau and Taiwan). In March 2023, we completed a phase III clinical trial of generalized myasthenia gravis (“gMG”). HBM4003 HBM4003 is a new generation all-human anti-CTLA-4 antibody that can be used to inhibit T-lymphocyte-associated antigen-4 (CTLA-4), one of the major negative cytotoxic factors regulating T-cell response. It is also the first internally developed molecule produced through our HCaB platform, and has advanced from drug candidate screening to clinical within three years. HBM4003 is the world's first all-human heavy chain antibody to enter clinical development, and in the pre-clinical stage, it has good characteristics compared to traditional anti-CTLA-4 antibodies. Compared to traditional anti-CTLA-4 antibodies, HBM4003 has significantly increased T-regulatory cell elimination mechanism and improved pharmacokinetics (“PK”) characteristics. At the same time, the potential for selective Treg cell elimination is enhanced by enhancing antibody-dependent cytotoxicity (“ADCC”) strategies. Improvements in efficacy and safety have been observed in clinical trials. We believe HBM4003 will break the immunosuppressive barrier of anti-tumor immunotherapy in solid tumors. HBM4003 is expected to overcome the efficacy and safety bottlenecks of existing CTLA-4 therapies and become a core product in the field of tumor immunotherapy. HBM7008 HBM7008 is a bispecific antibody targeting tumor-related antigens B7H4 and 4-1BB. Since it relies heavily on tumor-related antigens as mediated and cross-linked with T-cell activation, it not only has remarkable efficacy in co-stimulating T cells and inhibiting tumor growth, but is also expected to improve safety. HBM7008 is one of the all-human bispecific antibodies developed based on our HBICE platform, and is currently the only clinical-stage bispecific antibody against these two targets in the world. Its unique tumor expression specificity and immunomodulatory activity are expected to produce better curative effects in PD-L1 negative patients or patients resistant to PD1/PD-L1 immunotherapy drugs. With its novel biological mechanism of action and dual antibody design, it is hoped to avoid the risk of hepatotoxicity observed by 4-1BB in other products. In February 2023, we entered into an licensing and cooperation agreement with Cullinan Oncology, Inc. (together with its affiliates, “Cullinan”), under which we grant Cullinan an exclusive sublicensable license to develop any product containing or containing our bispecific antibody (HBM7008) against B7H4x4-1bb in the United States of America and its territories and territories (including the District of Columbia and Puerto Rico). HBM1020 HBM1020 is a first-of-its-kind all-human monoclonal antibody targeting B7H7 developed by the Harbour Mice platform. As a newly discovered member of the B7 family, the expression of B7H7 was found to not overlap with the expression of PD-L1 in various tumors, which may play a more important role in monitoring tumor cells to escape the epidemic. HBM1020 is the world's first and only clinical-stage product targeting B7H7. Thanks to its excellent product design and target characteristics, the unique expression of B7H7 was found to not overlap with the expression of PD-L1 in various tumors, representing another immune escape mechanism other than PD- (L) 1. In PD-L1 negative/refractory patients, B7H7 may play a more important role in tumor cells escaping surveillance. In May 2023, we began phase I clinical trials in the US. We believe HBM1020 has great potential to address significant unmet medical needs in the treatment of solid tumors. Committed to the discovery and development of differentiated antibody therapeutics in the fields of tumor immunity and autoimmune diseases, we have also explored and developed a number of projects, including novel and challenging monoclonal antibody projects, such as HBM1022 (CCR8), HBM1007 (a CD73-targeting monoclonal antibody with a dual mechanism of action), HBM9378 (a TSLP-targeted monoclonal antibody with better bioavailability), and HBM1047 (a CD200R1 targeted monoclonal antibody), and bispecific antibodies generated on the HBICE platform These antibodies have novel designs and differentiated mechanisms of action, such as HBM7020 (bCmaxCD3), HBM9027 (PD-L1xCD40), HBM7022 (Cldn18.2xCD3), and HBM7004 (B7H4xCD3). Furthermore, based on Harbour Mice's platform advantages, we have explored more immuno-oncology treatment pathways, such as HBM9033 (an ADC targeting MSLN). Leading drug innovation and discovery engine HBM4003 and many other projects were developed on our proprietary Harbour Mice platform. Our Harbour Mice platform is capable of producing classic double chain double light chain (H2L2) and heavy chain only (HCaB) forms of all-human monoclonal antibodies. The H2L2 platform can rapidly and on a large scale manufacture of typical double and double light immunoglobulin chain antibodies (H2L2) with modified whole-human variable regions to achieve endogenous affinity maturation and immune effect functions. The HCaB platform is a human-derived antibody platform that can manufacture different morphologies of “heavy chain only” antibodies (such as mRNA, nanoantibodies, bispecific/multispecific antibodies, cell therapy, and ADC), and has good development feasibility. With the proprietary technical knowledge accumulated from the HCaB platform, we have independently developed the HBICE platform, which focuses on generating differentiated bispecific antibodies based on HCaB immune cell connectors (which are expected to achieve tumor elimination effects that cannot be achieved with combination therapy). Combined with our monoclonal B cell screening platform, our high-efficiency antibody discovery engine has effectively fueled the company's innovation and sustainable growth. Based on the unique leading edge of the technology platform and the technical advantages of the team, we established Nona Biotech in 2022 to better empower industry innovation and provide our partners with assistance throughout the iTOITM (idea to IND application) process. Nona Biotech is an international biotechnology company that uses the technical advantages of the Harbour Mice platform and experienced therapeutic antibody discovery teams to provide overall solutions to partners from research institutes, biotech startups, and global biomedical giants around the world. One-stop antibody development services range from antigen preparation, animal immunity, single B cell screening, to lead antibody generation, engineering modification, developability assessment and related pharmacological evaluation. In 2023, Nona Biotech achieved significant results, strong business growth, and continuous platform innovation. In terms of business development, in 2023, we saw rapid growth in our service business and successfully authorized our assets to Pfizer. At the same time, we continue to advance technological innovation, and Nona Biotech has established four leading technology units based on HCaB, including protein engineering, coupling technology, delivery technology, and cell therapy. Commercial cooperation to maximize platform value We have global rights to use and develop platinum antibody platforms, enabling us to maximize the value of our platforms to address unmet global healthcare needs. We are expanding our business partnerships with leading academic institutions around the world and selecting industry partners focused on innovation and efficiency. Our Harbour Therapeutics' business partnership model is not limited to pure licensing, but also includes incubating co-development and joint ventures with academic institutions or other leading innovators in the industry on the next generation of innovative therapies. The platform has been recognized by more than 50 industry and academic partners. Based on our strong track record of cooperation, we believe our platform will have the potential to generate revenue and expand the scope of our business development work. In addition to collaborating through platform-based molecules and product pipelines, we are also focusing on more original and innovative project collaborations that are still in the early stages of development. By integrating the advantages of the industry-leading Harbour Mice and HCaB PlusTM platforms and the resources of our experienced therapeutic antibody development team, Nona Biotech provides a one-stop solution from I to ITM for therapeutic antibody discovery, engineering transformation and development with a flexible business model. We believe Nona Biotech will show us a new way to expand our collaborative network and maximize the value of our platform.